Clinical Trial

A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 17, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-09-16; most recent amendment 2024-10-15.
Status change: Not Yet Recruiting → Recruiting 2020-09-01
Trial Details
NCT Number NCT04093466
Lead Sponsor Beijing Konruns Pharmaceutical Co., Ltd.
Collaborators: Chinese Academy of Medical Sciences, West China Hospital, Beijing Tongren Hospital
Conditions Advanced Solid Tumor
Enrollment 126 participants
Start Date 2020-04-27
Primary Completion 2025-10 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-17